Dianthus director Moulder resigns; Read appointed as Class III director

Dianthus Therapeutics, Inc. /DE/

Leon O. Moulder, Jr. resigned from Board effective May 22, 2025, with no disagreement.
Board appointed Simon Read, Ph.D. as Class III director and to S&T and N&CG Committees.
Dr. Read receives initial option for 25,000 shares vesting over 3 years; cash compensation of $40k/yr plus $5k per committee.
Annual meeting elected Garcia and Soteropoulos as Class I directors; advisory vote approved exec compensation; Deloitte ratified as auditor.

item 5.02item 5.07

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Simon Read

Class III director

DNTH · Dianthus Therapeutics, Inc. /DE/

Effective: 2025-05-22
Filed: May 22, 2025 23:59 UTC

On May 22, 2025, the Board appointed Simon Read, Ph.D., as a Class III director of the Company and as a member of both the Science and Technology Committee of the Board (the “S&T” Committee) and the Nominating and Corporate Governance Committee of the Board (the “N&CG” Committee), effective immediately.

Departed

Leon O. Moulder, Jr.

Director

DNTH · Dianthus Therapeutics, Inc. /DE/

Effective: 2025-05-22
Successor: Simon Read
Filed: May 22, 2025 23:59 UTC

On May 22 2025, Leon O. Moulder, Jr., a member of the Board of Directors (the “Board”) of Dianthus Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board effective immediately.

Source: SEC EDGAR

accession 0000950170-25-076304

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.